Clinical Trials Logo

Secondary Sclerosing Cholangitis clinical trials

View clinical trials related to Secondary Sclerosing Cholangitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05396755 Terminated - Clinical trials for Secondary Sclerosing Cholangitis

Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis (BISCIT)

BISCIT
Start date: November 14, 2022
Phase: N/A
Study type: Interventional

This is a randomized, open-label, controlled, parallel group, multicenter clinical trial. Patients with confirmed secondary sclerosing cholangitis (SSC-CIP) will be randomized either in the intervention group undergoing scheduled invasive evaluation of the biliary tract or in the control group treated with non-interventional standard of care to demonstrate that programmed endoscopic therapy compared to a conservative strategy reduces the occurrence of treatment failures.

NCT ID: NCT05233553 Completed - COVID-19 Clinical Trials

SSC-COVID in Patients After COVID-19

Start date: March 1, 2020
Phase:
Study type: Observational

Analysis of occurrence of SSC-COVID in SARS-CoV-2-patients after the first wave of COVID-pandemic

NCT ID: NCT02701166 Recruiting - Clinical trials for Primary Sclerosing Cholangitis

The Effect of Bezafibrate on Cholestatic Itch

FITCH
Start date: February 2016
Phase: Phase 3
Study type: Interventional

Randomized double blind placebo controlled trial to evaluate the antipruritic effect of bezafibrate in patients with moderate to severe cholestatic itch.

NCT ID: NCT02545309 Active, not recruiting - Clinical trials for Secondary Sclerosing Cholangitis

Secondary Sclerosing Cholangitis in Critically Ill Patients

SSC-CIP
Start date: December 21, 2015
Phase:
Study type: Observational

SSC-CIP is increasing in patients after critical illness. Pathogenesis is still largely unclear. The investigators hypothesize that genetic variants of biliary transporter genes are frequent in patients with SSC-CIP. In approximately 140 patients and controls the rate of genetic variants in biliary transporter genes, gut permeability and gut microbiome as well as bone health will be studied.